|Bid||2.1040 x N/A|
|Ask||2.2120 x N/A|
|Day's Range||2.1040 - 2.2360|
|52 Week Range||1.9720 - 3.9200|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for 4R0.SG
Asuragen, a Bio-Techne brand (NASDAQ: TECH) and Oxford Nanopore Technologies plc (Oxford Nanopore) (LSE: ONT), today announce a collaboration to develop assays designed to deliver more accurate and reliable options for reproductive health and carrier screening. Asuragen will leverage its gold-standard PCR technology with Oxford Nanopore's any-read-length DNA sequencing capabilities to develop the first sequencing system to identify the most challenging yet high prevalence carrier genes in a sing
By integrating Remora into MinKNOW the analysis of epigenetic modifications becomes seamless as it now runs in parallel to standard basecalling. This release complements the simplicity of native DNA sample preparation, which can be done in just 10 minutes using the same run, so at no additional cost.
With the latest updates, nanopore sequencing can now deliver very accurate, comprehensive data outputs, at high yields, with the ability to sequence short or long fragments, in real time and capture all variant types in one experiment, on one platform. Oxford Nanopore technology enables users to fit the technology to their biological question.